Jaguar Health Inc (JAGX)

NASDAQ
1.4600
-0.0600(-3.95%)
After Hours
1.4501
-0.0099(-0.6781%)
- Real-time Data
  • Volume:
    2,343,690
  • Bid/Ask:
    1.4600/1.4700
  • Day's Range:
    1.4500 - 1.5100

JAGX Overview

Prev. Close
1.46
Day's Range
1.45-1.51
Revenue
9.76M
Open
1.5
52 wk Range
0.1851-4.47
EPS
-0.9
Volume
2,343,690
Market Cap
200.49M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
9,884,940
P/E Ratio
-
Beta
1.56
1-Year Change
115.47%
Shares Outstanding
137,320,281
Next Earnings Date
Aug 19, 2021
What is your sentiment on Jaguar Health Inc?
or
Market is currently closed. Voting is open during market hours.

Jaguar Health Inc News

Jaguar Health Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellSellSell
SummaryStrong SellStrong SellStrong SellStrong SellSell

Jaguar Health Inc Company Profile

Jaguar Health Inc Company Profile

Employees
34

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.

Read More
  • 😭😭😭😭I lose my money average 2.80
    0
    • Average 3:50
      0
  • worst stock I bought!!
    0
    • buy buy hold 🚀🚀
      0
      • buy bye buy buy will go to $3.00 next week.
        0
      • 😟 where we are?😐😐
        0
    • spac from India BSE ?
      0
      • SPAC
        1
        • SPAC from INDIA BSE ?
          0
      • how long it takes to go 3 or more ??
        0
        • this week for sure not more than 5 days . how many shares you own and when you bought these in which price please ?
          0
        • Panagiotakis To kalo paidi3000 share .price 2.80
          0
      • Switch to XELA guys and make money
        4
        • Sold it can't wait more, no positive news at all.
          0
          • what happened ?? any good news?
            1
            • 16 Jun it will happen I hope so
              0
              • why 16th
                0
            • Back to 1.770
              8
              • back to 1.5
                0
            • i said this month it will surpass 3
              0
              • easy target
                0
              • well done
                0
              • geia sou Mike simera pou tha paei auti i metoxi ti problepsi exeis ? Yannis apo Rodo.
                0
            • 👍👍👍👍👍
              0
              • 🚀
                0
                • 4 $ today
                  1
                  • New drug?
                    0
                    • guys how long take to go 3 or 4?
                      0
                      • very quick....
                        0
                      • it will happen this month
                        0
                    • JAGX🚀
                      1
                      • bagholders unite
                        0
                        • I read about a possible merger taking place. Is it real or potential news? Forgive me, I don't understand how a stock that was quoted around $ 7,000, a very long time ago, is not attractive. It remains a mystery. Can any of you tell me something about it?
                          0
                          • Evofem Biosciences EVFM Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women
                            0
                            • HELLO?
                              0
                              • hello. are you waiting for this stock to jump too??
                                0
                              • Yes, supposly it is a good company, but all depends of the buyers and sellers. I think.
                                0
                              • It's me.
                                0
                            • up
                              1
                              • TTM
                                0
                                • I just turned 18 so JAGX was my first ever share, bought 35 of those baddies so lets get it to $2 !!!
                                  1
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.